STEP-HFpEF DM
To evaluate the effect of semaglutide (GLP-1) in patients with obesity, Type II diabetes and chronic HFpEF on heart failure disease-specific symptoms, health status and quality of life, when compared with placebo
- Stage
- klaar
- Medicine
- semaglutide
- Population
- Hartfalen
- Phase
- III
- First Patient In
- 13 August 2021
- Last Patient In
- 1 August 2022
- Last Patient Last Visit
- 24 August 2023
National Lead
dr. P van der Meer
Cardioloog
Study Director
dr. C.A. da Fonseca
Cardioloog
Office Contact
